What is the 13F Pro Quality Score for ELMD?

13F Pro ranks Electromed, Inc. (ELMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELMD's current score at https://13fpro.ai/research/ELMD (free sign-up required for the full ranking).

Which hedge funds own the most ELMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ELMD include J.E. Simmons & Co., P.C., BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ELMD as soon as new 13F filings post.

Where does 13F Pro source ELMD data?

All Electromed, Inc. fundamentals and ownership data come directly from SEC EDGAR. Electromed, Inc. files with the SEC under CIK 1488917. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELMD in?

Electromed, Inc. (ELMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELMD research updated on 13F Pro?

ELMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Electromed, Inc.(ELMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1488917 ELMD stock profile & AI dashboard →

13F Pro Quality Score

64.5/100

Rank #630 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

76.7/100

Profitability

79.4/100

Balance Sheet

95.8/100

Earnings Quality

85.6/100

Free Cash Flow

66.0/100

Institutional Flow

28.4/100

Revenue Scale

13.9/100

Dilution Risk

24.2/100

ELMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Electromed, Inc. (ELMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELMD at 64.5/100 on a 32-signal composite quality model, placing it at rank #630 of 2,879 stocks — the top 25% of the AI-ranked universe. ELMD scores in the top quartile across balance sheet strength (95.8), earnings quality (85.6), profitability (79.4). Areas of concern include revenue scale (13.9) and institutional flow (28.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Electromed, Inc. reports quarterly revenue of $18.6M, net income of $3.0M, an operating margin of 20.3%. Top institutional holders of ELMD by reported 13-F value include J.E. Simmons & Co., P.C., BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ELMD trades on the NYSE exchange and files with the SEC under CIK 1488917. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Electromed, Inc. directly from SEC EDGAR. Electromed, Inc.'s 13F Pro composite quality score has ranged between 8 and 85 since 2021, currently 64.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Electromed, Inc.

Quirks, history, and lore behind ELMD — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on NYSE American · headquartered in Minnesota · focused on respiratory care.
2
The Numbers
Annual revenue in the range of $20–30 million — tiny by Wall Street standards, but its niche is deep: airway clearance therapy for patients with chronic pulmonary conditions.
3
The History
Founded in the early 2000s, the company commercialized technology originally developed to help patients with bronchiectasis, cystic fibrosis, and COPD clear mucus from their lungs.
4
The Secret
Its core product uses high-frequency chest wall oscillation — essentially a wearable vest that vibrates to shake loose mucus — making breathing easier for patients who struggle daily.
5
The Lore
The company sells directly to patients and caregivers and works closely with insurers and Medicare, navigating the notoriously tricky world of durable medical equipment reimbursement.
6
The Giveaway
Its flagship product, the SmartVest, is a high-frequency oscillating airway clearance system — and its ticker, ELMD, is a pretty strong hint at the "electro" in its name.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$18.6M

Net Income

Q3 2026

$3.0M

Free Cash Flow

Q3 2026

$3.3M

Operating Margin

Q3 2026

20.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.0% YoY

$64.0MFY 2025

FY22 $41.7MFY23 $48.1MFY24 $54.7MFY25 $64.0M

Net Income

+46.3% YoY

$7.5MFY 2025

FY22 $2.3MFY23 $3.2MFY24 $5.2MFY25 $7.5M

Operating Income

+46.8% YoY

$9.7MFY 2025

FY22 $3.0MFY23 $4.0MFY24 $6.6MFY25 $9.7M

EPS (Diluted)

+46.6% YoY

$0.85FY 2025

FY22 $0.26FY23 $0.36FY24 $0.58FY25 $0.85

Total Assets

+3.0% YoY

$53.8MFY 2025

FY22 $41.4MFY23 $45.8MFY24 $52.2MFY25 $53.8M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+25.7% YoY

$11.4MFY 2025

FY22 $-686.0KFY23 $1.3MFY24 $9.1MFY25 $11.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$64.0M +17.0%	$54.7M +13.8%	$48.1M +15.4%	$41.7M +16.5%	$35.8M +10.1%	$32.5M
Net Income	$7.5M +46.3%	$5.2M +62.7%	$3.2M +37.4%	$2.3M -2.4%	$2.4M -43.2%	$4.2M
Operating Income	$9.7M +46.8%	$6.6M +64.2%	$4.0M +34.9%	$3.0M -5.4%	$3.1M -38.6%	$5.1M
EPS (Diluted)	$0.85 +46.6%	$0.58 +61.1%	$0.36 +38.5%	$0.26 -3.7%	$0.27 -42.6%	$0.47
Total Assets	$53.8M +3.0%	$52.2M +14.0%	$45.8M +10.7%	$41.4M +11.5%	$37.1M +11.6%	$33.2M
Total Debt	—	—	—	—	$33.0K -54.2%	$72.0K
Operating Cash Flow	$11.4M +25.7%	$9.1M +589.5%	$1.3M +291.7%	$-686.0K -122.3%	$3.1M -26.7%	$4.2M

AI Insight: ELMD Financial Trends

Revenue growth accelerating to 19% YoY while operating income doubled, but operating cash flow remains volatile and lumpy.

• Revenue grew from $15M (Q2 2024) to $19M (Q1 2026), a 27% increase over 9 quarters. Q4 2025–Q1 2026 flat at $19M.

• Operating income expanded from $2M (Q2 2024) to $4M (Q4 2025, Q1 2026), doubling over the period.

• Net income improved from $1M–$2M range to $3M in Q4 2025–Q1 2026, a 50% increase year-over-year.

⚠ Operating cash flow collapsed to $0M in Q3 2025 despite $17M revenue; latest quarter shows $3M but pattern is erratic.

⚠ Equity increased from $45M (Q2 2024) to $49M (Q1 2026), but Q3 2025 dipped to $41M, signaling working capital volatility.

AI Insight: ELMD Ratio Trends

Operating margin surged to 20.3% in Q1 2026, driven by sustained profit expansion across all return metrics through 2025.

• OpMargin expanded 250bp from Q2 2024 (15.7%) to Q1 2026 (20.3%); NPM climbed 390bp to 16.2% over same period.

• ROIC accelerated to 30.6% in Q1 2026 from 21.0% in Q2 2024, a 960bp gain reflecting capital efficiency gains.

• ROE and ROA both reached 24.4% and 20.2% respectively in Q1 2026, near 2-year highs with consecutive quarter improvements.

⚠ OpMargin volatility visible: 13.2% in Q3 2024, 19.2% in Q4 2025, then 20.3% in Q1 2026. Monitor consistency.

Get alerted when ELMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Electromed, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELMD

J.E. Simmons & Co., P.C.
$11.5M492,822 sh
BlackRock, Inc.
$10.7M458,845 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.8M335,028 sh
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$5.3M224,520 sh
TWO SIGMA INVESTMENTS, LP
$4.8M203,600 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.7M201,893 sh
DIMENSIONAL FUND ADVISORS LP
$4.2M178,270 sh
GAMCO INVESTORS, INC. ET AL
$3.3M142,000 sh
RENAISSANCE TECHNOLOGIES LLC
$2.9M124,004 sh
STATE STREET CORP
$2.5M106,363 sh

Fund	Value	Shares
J.E. Simmons & Co., P.C.	$11.5M	492,822
BlackRock, Inc.	$10.7M	458,845
VANGUARD CAPITAL MANAGEMENT LLC	$7.8M	335,028
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	$5.3M	224,520
TWO SIGMA INVESTMENTS, LP	$4.8M	203,600
GEODE CAPITAL MANAGEMENT, LLC	$4.7M	201,893
DIMENSIONAL FUND ADVISORS LP	$4.2M	178,270
GAMCO INVESTORS, INC. ET AL	$3.3M	142,000
RENAISSANCE TECHNOLOGIES LLC	$2.9M	124,004
STATE STREET CORP	$2.5M	106,363

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELMD on your watchlist

Track score changes the day Electromed, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELMD a good stock to buy?

13F Pro's AI-powered analysis of Electromed, Inc. (ELMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELMD are available on the ELMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ELMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Electromed, Inc.'s investment landscape.